| Bioactivity | Emfizatamab (GNC-038) is a tetra-specific antibody. Emfizatamab activates CD3 and 4-1BB on T cells, and targets CD19 or PD-L1 on tumor cells, thereby leading to T cell-mediated cytolysis of human leukemia and lymphoma cells[1][2]. |
| CAS | 2559704-23-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jianxiang Wang, et al. GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.Meeting Abstract: 2023 ASCO Annual Meeting I. May 31, 2023 [2]. Jahan Salar Khalili, et al. Abstract 5681: Tetra-specific antibody GNC-038: guidance and navigation gontrol (GNC) molecule development for treatment of CD19+ malignancies. Cancer Res (2023) 83 (7_Supplement): 5681. |